1Jenab-Wolcott J, Giantonio BJ. Bevacizumab: Current indications and future development for management of solid tumors [J]. Expert Opin Biol Ther, 2009, 9 (4):507.
2Jain R K, et al. Lessons from phase Ⅲ clinical trials on anti-VEGF therapy for cancer [J]. Nat Clin Pratt Oncol, 2006, 3 : 24.
3Chase JL. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer [ J ]. Pharmacotherapy, 2008, 28 ( 11 Pt 2) : S23.
4Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: A multidisciplinary phase Ⅱ study [J]. J Clin Oncol, 2009, 27(18) :3020.
5Willett CG, Kozin SV, Duda DG. et al. Combined VEGF- targeted therapy and radiotherapy for rectal cancer: Theory and clinical practice [J]. Semin Oncol, 2006, 33 (5 Suppl 10): s35.
6Ellis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer [J]. Semin Oncol, 2006, 33:S1.
7Sandier A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer [ J ]. N Engl J Med, 2006, 355 : 2542.
8Motzer RJ, et al. Sunitinib versus interferon α in metastatic renal-cell carcinoma [J]. N Engl J Med, 2007, 356: 115.
9Escudier B, et al. Sorafenib in advanced clear-cell renal-cell carcinoma [J]. N Engl J Med, 2007, 356 : 125.
10Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma [J]. Cancer, 2008, 112:250.
